AU Patent

AU2019339410A1 — Organoid compositions for the production of hematopoietic stem cells and derivatives thereof

Assigned to Cincinnati Childrens Hospital Medical Center · Expires 2021-04-15 · 5y expired

What this patent protects

The instant disclosure relates to compositions derived from precursor cells, and methods of using such compositions, for the manufacture of hematopoietic stem cells (HSCs) or derivative immune cells. More particularly, methods for obtaining hematopoietic stem cells from organoid …

USPTO Abstract

The instant disclosure relates to compositions derived from precursor cells, and methods of using such compositions, for the manufacture of hematopoietic stem cells (HSCs) or derivative immune cells. More particularly, methods for obtaining hematopoietic stem cells from organoid tissue or cultures comprising organoids are disclosed, wherein the organoid tissue or cultures comprise liver or colonic tissue derived from precursor cells (such as embryonic stem cells or induced pluripotent stem cells), via directed differentiation.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019339410A1
Jurisdiction
AU
Classification
—
Expires
2021-04-15
Drug substance claim
No
Drug product claim
No
Assignee
Cincinnati Childrens Hospital Medical Center
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.